Skip to main content
. 2024 Sep 10;271(10):6991–6999. doi: 10.1007/s00415-024-12647-z

Fig. 2.

Fig. 2

Biomarkers for clinical disease severity in MSA. CSF and plasma levels of GFAP and NfL in MSA compared to UMSARS I + II scores. Multiple regression analysis adjusting for age-identified GFAP levels in CSF and plasma as significant predictor of baseline UMSARS I + II scores in MSA patients, but not NfL